Reference

1. Pauwels R. The effects of theophylline on airway inflammation. Chest. 1987 Jul;92(1 SUPPL.):32S-37S. 
2. Sharma A, Adiga S, Chogtu B, Mohapatra AK, Magazine R. Comparing the efficacy and influence on the quality of life of three classes of drugs used in bronchial asthma - a prospective study. J Clin Diagn Res [Internet]. 2014 Sep [cited 2023 Sep 21];8(9):HC13-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25386456
3. Agliati G. Effects of a short course of treatment with acebrophylline on the mucus rheological characteristics and respiratory function parameters in patients suffering from chronic obstructive pulmonary disease. Journal of International Medical Research. 1996;24(3):302–10. 
4. Pozzi E. Acebrophylline: an airway mucoregulator and anti-inflammatory agent. Monaldi Arch Chest Dis [Internet]. 2007 [cited 2023 Sep 21];67(2):106–15. Available from: https://pubmed.ncbi.nlm.nih.gov/17695695/
5. Gildea TR, Khatri SB, Castro M. Bronchial thermoplasty: A new treatment for severe refractory asthma. Cleve Clin J Med. 2011 Jul;78(7):477–85. 
6. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma Control during the Year after Bronchial Thermoplasty. New England Journal of Medicine. 2007 Mar 29;356(13):1327–37. 
7. Cazzola M, Donner CF. Long-acting ?2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs. 2000;60(2):307–20. 
8. Mangprayool T, Kupittayanant S, Chudapongse N. Participation of citral in the bronchodilatory effect of ginger oil and possible mechanism of action. Fitoterapia [Internet]. 2013 [cited 2023 Sep 21];89(1):68–73. Available from: https://pubmed.ncbi.nlm.nih.gov/23685048/
9. Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol [Internet]. 2011 [cited 2023 Sep 21];128(6). Available from: https://pubmed.ncbi.nlm.nih.gov/22035879/
10. Abril AG, Pazos M, Villa TG, Calo-Mata P, Barros-Velázquez J, Carrera M. Proteomics Characterization of Food-Derived Bioactive Peptides with Anti-Allergic and Anti-Inflammatory Properties. Nutrients [Internet]. 2022 Oct 1 [cited 2023 Sep 21];14(20). Available from: https://pubmed.ncbi.nlm.nih.gov/36297084/
11. Kim S Il, Park CY, Fordjuor G, Lee JH, Lee JS, Lee JE. Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. BMC Ophthalmol [Internet]. 2019 Nov 8 [cited 2023 Sep 21];19(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31703568/
12. Vasi? J, Dimi? D, Antonijevi? M, Avdovi? EH, Milenkovi? D, Nakarada ?, et al. The Electronic Effects of 3-Methoxycarbonylcoumarin Substituents on Spectral, Antioxidant, and Protein Binding Properties. Int J Mol Sci [Internet]. 2023 Jul 1 [cited 2023 Sep 21];24(14). Available from: https://pubmed.ncbi.nlm.nih.gov/37511579/
13. S S, T O, S M, T A, M T, Y S, et al. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology [Internet]. 1983 [cited 2023 Sep 21];20(5):677–83. Available from: https://pubmed.ncbi.nlm.nih.gov/6375756/
14. Lhermitte M, Lamblin G, Lafitte JJ, Degand P, Roussel P, Mazzuca M. Human, bronchial-mucus glycoproteins: a comparison between chemical properties and affinity for lectins. Carbohydr Res. 1981 Jun 1;92(2):333–42. 
15. Tapadar SR, Das M, Chaudhuri AD, Basak S, Mahapatra ABS. The Effect of Acebrophylline vs Sustained Release Theophylline in Patients of COPD- A Comparative Study. J Clin Diagn Res [Internet]. 2014 Sep 20 [cited 2023 Jun 2];8(9):MC11–4. Available from: https://pubmed.ncbi.nlm.nih.gov/25386474/
16. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med [Internet]. 2004 [cited 2023 Jun 2];3(4):247–68. Available from: https://pubmed.ncbi.nlm.nih.gov/15350163/
17. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med [Internet]. 2007 Sep 15 [cited 2023 Jun 2];176(6):532–55. Available from: https://pubmed.ncbi.nlm.nih.gov/17507545/
18. Gupta PR. Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India [Internet]. 2010 Apr 1 [cited 2023 Sep 21];27(2):46–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20616932
19. Kuriachan S, Mohan Babu Amberkar V, Mohan MK, Shahul HA, Meena kumari K. Acebrophylline-induced angioedema. Indian J Pharmacol [Internet]. 2015 Mar 1 [cited 2023 Sep 21];47(2):219–20. Available from: https://pubmed.ncbi.nlm.nih.gov/25878387/
20. Hull JD, Lyon RA. In vitro pharmacology of ambroxol: Potential serotonergic sites of action. Life Sci. 2018 Mar 15;197:67–72. 
21. Sved S, McGilveray IJ, Beaudoin N. The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. Biopharm Drug Dispos [Internet]. 1981 [cited 2023 Sep 21];2(2):177–84. Available from: https://pubmed.ncbi.nlm.nih.gov/7248481/
22. Goldrub N, Soares VRZ, Hamoui A, et al. Therapeutic activity and tolerability profile of acebrophylline. Advan Ther 1992; 9: 107-11
23. Milvio C, Borellini P, Benazzi, et al. Effetti clinici del teofillin-acetato di ambroxol. Giorn Ist Ric Clin Ter 1985; 4: 77-80
24. Fracchia C, Della Torre M, Zanotti E, et al. Valutazione dell’attività di acebrofillina (P3011): studio controllato verso ambroxol. Rass Pat App Resp 1987; 1: 177-181
25. Mak, G., and Hanania, NA. (2012). New bronchodilators. Current Opinion in Pharmacology. 12, 238-245
26. Page, CP. (2010). Doxofylline: a “novofylline”. Pulmonary pharmacology & therapeutics, 23(4), 231-234.